Sites Menu > Medication Information - Antithrombotics


Medication Information - Antithrombotics


Heparin (Systemic)

from WebMd

RIVAROXABAN (BAY 59-7939), A POSSIBLE REPLACEMENT FOR WARFARIN

A new Factor Xa inhibitor is in development. It looks promising up through Phase II testing. In a safety study, oral BAY 59-7939 in single doses up to 80 mg was safe and well tolerated and was not associated with an increased risk of bleeding compared with placebo. Pharmacodynamic effects (inhibition of factor Xa activity, prothrombin time, activated partial thromboplastin time, and Hep Test) and plasma concentration profiles were dose-dependent. Maximum inhibition of factor Xa activity was achieved 1 to 4 hours after administration of BAY 59-7939 and ranged from 20% to 61% for the 5- to 80-mg doses. Last updated April 8, 2007

Self-Managed Long-Term Low-Molecular-Weight Heparin Therapy: The Balance of Benefits and Harms

The American Journal of Medicine. Volume 120, Issue 1 , January 2007, Pages 72-82.e3. Conclusion: Our study shows that LMWH is similar in effectiveness to the usual-care vitamin K antagonist treatment for preventing recurrent venous thromboembolism in a broad spectrum of patients. It causes less harm and enhances the clinicians' therapeutic options for patients with proximal deep vein thrombosis. Our findings reported here suggest the possibility of a broader role for long-term LMWH in selected patients.

Danaparoid & Lepirudin

Alternative Pharmacologic Agents for Prophylactic & Therapeutic Anticoagulation in Patients with Heparin-induced Thrombocytopenia

Innohep


ODP: Heparin

Links to heparin sites.

Fragmin« (dalteparin sodium injection)

Prescribing Information - April 2007

Heparin-induced thrombocytopenia: an update

Thrombosis Journal 2005, 3:14 doi:10.1186/1477-9560-3-14

Enoxaparin Sodium Subcutaneous - Lovenox

WebMD Health

Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty

Annals of Internal Medicine; 15 October 2002, Volune 137, Number 8, Pages 649-659

AN EDITORIAL ABOUT BRIDGING THERAPY

IT MUST BE NOTED THAT THE US FDA HAS NEVER GIVEN APPROVAL TO USING ANY HEPARIN OR LOW MOLECULAR WEIGHT HEPARIN AS A BRIDGE THERAPY WHEN WARFARIN MUST BE STOPPED. Last reviewed July 8, 2005

Establishing Therapeutic Range for Heparin

May 2004

Giving LMWH shots

from Tamara on the FVL mailing list

Enoxaparin (Low Molecular Weight Heparin) Guidelines


ARIXTRA« (fondaparinux sodium)

Prescribing Information - October 2005

Heparin-induced thrombocytopenia: the female factor

Blood, 1 November 2006, Vol. 108, No. 9, pp. 2884-2885.

Lovenox

Enoxaparin sodium (LMW Heparin). Official manufacturer's site.

Tinzaparin (Innohep)

This information has been developed and provided by an independent third-party source. Merck & Co., Inc. does not endorse and is not responsible for the accuracy of the content, or for practices or standards of non-Merck sources.

Otamixaban - a Factor Xa Inhibitor being studied as a possible replacement for warfarin

The advantage that is being sought among this class of drugs is lowered bleeding risk compared to warfarin. If this proves true, this class of drugs will be very advantageous. When otamixaban was administered IV to healthy, male subjects, it was found to have rapid plasma distribution and elimination, low intersubject variability and was excreted by both the liver and the kidney. Last updated April 8, 2007

Heparin in Children

May 2004

Dalteparin Sodium (porcine) Subcutaneous - Fragmin

WebMD Health

Innohep

Tinzaparin sodium (LMW Heparin). Official manufacturer's site.

Arixtra SubQ

Fondaparinux is a type of "blood thinner" medication (heparinoids) used to help prevent the formation of blood clots following abdominal, hip or knee surgery.

Arixtra« during pregnancy

Last Updated: 3/13/2007. Neither low molecular weight heparins (LMWH; in the U.S.: Fragmin®, Lovenox®, or Innnohep®) nor Fondaparinux (=Arixtra®) have FDA approval to be used in pregnancy. This reflects that neither one has been tested in any larger trials in pregnant women. Thus, it is not known whether one is more or less effective as a blood thinner during pregnancy than the other, or more or less safe. Both, low molecular weight heparins and Arixtra®, are categorized as "class B" drugs during pregnancy, meaning that "animal studies show no risk or adverse fetal effects, but controlled human 1st trimester studies are not available; there is no evidence of 2nd or 3rd trimester risk; fetal harm is possible but unlikely". In pregnant women who need blood thinners, most physicians probably use LMWH and not Arixtra®, because LMWHs have been in use much longer and there is much more clinical experience with them during pregnancy. While there are a large number of publications reporting the use of LMWH during pregnancy, for Arixtra® there are only a few case reports (references 1-4). Arixtra® is, therefore, typically only used in the pregnant woman with a history or heparin allergy, called "HIT" (or heparin induced thrombocytopenia).

Aventis - Lovenox Prescribing Information

enoxaparin sodium injection. Rx only. Rev. (c) 2007


[1] [2] Next



 

 

The APS Foundation of America, Inc. website and forums are both volunteer run and funded by donations to the APSFA.

Website hosted by Dreamhost. Website created and maintained by Heidi P.

DISCLAIMER: APS Foundation of America, Inc. website is not intended to replace standard doctor-patient visits, physical examination, and medical testing. Information given to members is only an opinion. All information should be confirmed with your personal doctor. Always seek the advice of a trained physician in person before seeking any new treatment regarding your medical diagnosis or condition. Any information received from APS Foundation of America, Inc. website is not intended to diagnose, treat, or cure. This site is for informational purposes only. Please note that we will be listing all donor or purchaser's names on the Donor page of our foundation site. If you do not want your name listed, please contact us to opt out. If you think you may have a medical emergency, call your doctor or 911 immediately.

APS Foundation of America, Inc. will be building a database with your email, name and address information for future mailings. Your information will be kept confidential and not sold to any third parties. You may opt out at anytime by emailing us.

APSFA ©2005-2016 | APSFA Privacy Policy | APSFA Advertising Policy | 501(c)3 Public Charity EIN #203085295